Ventrus Biosciences Cash Flow - Annual (NASDAQ:ASMB)

Add to My Stocks
$36.79 $2.03 (5.84%) ASMB stock closing price Sep 20, 2018 (Closing)

For analyzing any company like Ventrus Biosciences from an investment perspective, its important to check the cash flow statement. The profit-loss statement shows Ventrus Biosciences profits, the balance sheet shows Ventrus Biosciences debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Ventrus Biosciences saw a cash impact of $67.24M from the issuance of ASMB shares. The cash flow statement helps in the Ventrus Biosciences stock analysis by providing more information for evaluating changes in assets, liabilities and equities. Ventrus Biosciences saw a outflow of $-15.64M from investing activities for 2017.

View details of Ventrus Biosciences cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec201720162015201420132012201120102009
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow-------2.33M-
Net Increase (Decrease) in Assets Liabilities44.36M3.75M1.78M-2.51M-0.11M-1.96M-3.06M-
Cash From (used in) Discontinued Operations---------
Other Adjustments Net-5.54M7.9M11.31M1.71M3.17M6.97M10.8M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.86M-0.14M-0.05M-0.14M-0.01M--0.01M--
Acquisition Disposition of Subsidiaires---------
Increase (Decrease) in Investments-14.77M36.34M-64.79M------
Other Cash Inflow (Outflow) from Investment Activities----0.08M-----
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares67.24M-81.56M16.72M24.37M4.16M49.98M15.18M-
Issuance (Repayment) of Debt Securities-------1.21M1.75M1.9M
Increase (Decrease) in Bank & Other Borrowings-------1.57M3.52M1.72M
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities--------0.75M-0.07M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash---------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year28.57M27.1M29.09M27.06M20.48M36.97M14.57M--
Cash & Equivalents at Year End82.03M28.57M27.1M29.09M27.06M20.48M36.97M14.57M-
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

While Ventrus Biosciences stock price history provides the price history of a stock, Ventrus Biosciences stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Ventrus Biosciences is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Ventrus Biosciences stock price movement.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Ventrus Biosciences gained $1.86M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: Ventrus Biosciences used $-15.64M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash flow from financing activities shows the flow of cash between Ventrus Biosciences and its owners and creditors and was $67.24M for 2017. Financing activities allow a company to raise capital, and repay bondholders.

Key Financial Ratios For Ventrus Biosciences Cash Flow

Annual Cash Flow Statements For Assembly Biosciences Inc Peers

Chimerix cash flow, Celator Pharma cash flow, CytoDyn cash flow, Paratek Pharma cash flow